Alveolar epithelial cells orchestrate DC function in murine viral pneumonia

Barbara Unkel,1 Katrin Hoegner,1 Björn E. Clausen,2 Peter Lewe-Schlosser,3 Johannes Bodner,4 Stefan Gattenloechner,5 Hermann Janßen,6 Werner Seeger,1 Juergen Lohmeyer,1 and Susanne Herold1

1Department of Internal Medicine II, University of Giessen and Marburg Lung Center (UGMLC; member of the German Lung Research Center), Giessen, Germany; 2Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; 3Center for Radiation Therapy, 4Department of General and Thoracic Surgery, and 5Department of Pathology, UGMLC, Giessen, Germany; 6Department of Surgery II, Hospital Dueren, Dueren, Germany.

Influenza viruses (IVs) cause primary viral pneumonia in humans with progression to lung failure. Pulmonary DCs are key players in the antiviral immune response, which is crucial to restore alveolar barrier function. The mechanisms of expansion and activation of pulmonary DC populations in lung infection remain widely elusive. Using mouse BM chimeric and cell-specific depletion approaches, we demonstrated that alveolar epithelial cell (AEC) GM-CSF mediates recovery from IV-induced injury by affecting lung DC function. Epithelial GM-CSF induced the recruitment of CD11b+ and monocyte-derived DCs. GM-CSF was also required for the presence of CD103+ DCs in the lung parenchyma at baseline and for their sufficient activation and migration to the draining mediastinal lymph nodes (MLNs) during IV infection. These activated CD103+ DCs were indispensable for sufficient clearance of IVs by CD8+ T cells and for recovery from IV-induced lung injury. Moreover, GM-CSF applied intratracheally activated CD103+ DCs, inducing increased migration to MLNs, enhanced viral clearance, and attenuated lung injury. Together, our data reveal that GM-CSF–dependent cross-talk between IV-infected AECs and CD103+ DCs is crucial for effective viral clearance and recovery from injury, which has potential implications for GM-CSF treatment in severe IV pneumonia.

Introduction
Influenza viruses (IVs) may cause primary viral pneumonia in humans with rapid progression to lung failure and fatal outcome (1). Histopathologic and clinical features of IV-induced lung injury in humans resemble those of other forms of adult respiratory distress syndrome (ARDS), characterized by apoptotic alveolar epithelial damage, loss of alveolar barrier function, and severe hypoxemia (1–3). As soon as the infection spreads from the upper to the lower respiratory tract, alveolar epithelial cells (AECs) become primary targets for productive IV replication (3–5). At the same time, AECs release innate immune mediators, which activate myeloid mononuclear phagocytes such as alveolar macrophages or DCs or recruit their precursors to the site of infection (6). Combining sensor and effector functions of innate immunity, the lung epithelium has recently been ascribed an important role in coordinating, maintaining, and balancing the phagocyte-mediated antiviral host response (7). The molecular signals involved in this cellular cross-talk between alveolar epithelium and local mononuclear phagocyte subsets during the host response to viral infection in situ, however, remain largely elusive.

Rapid and effective clearance of IVs from the distal lung is crucial for recovery from IV-induced lung injury. Different CD11c–MHCII– pulmonary DC subsets critically contribute to pulmonary host defense (8, 9). In mice, these include CD11b+CX3CRI+CD103– and CD103+langerin+CD11b– parenchymal DCs, which form an elaborate network in immediate proximity to AECs to rapidly encounter foreign antigen in the alveolar airspaces and lung interstitium and migrate to the draining mediastinal lymph nodes (MLNs) (10). Several reports demonstrate a key role for the pulmonary CD103+langerin+CD11b– DC subset in antiviral immunity in vitro and in vivo (11, 12), and elimination of CD103+langerin+ DCs during IV infection severely impairs induction of the CD8+ T cell–mediated response and delays viral clearance (13).

Under steady-state conditions, pulmonary CD11b+ and CD103+ DCs arise from circulating GR-1hi monocytes and pre-DCs, respectively, and replenishment of their resident pools depends on Flt3/ Flt3L and M-CSF receptor (M-CSFR) (14). During lung infection or inflammation, the inflammatory DC subsets in particular, CD11b+ DCs and the less differentiated monocyte-derived DCs (mo-DCs), are expanded from the circulating GR-1hi monocyte pool, whereas the numbers of CD103+ DCs in lung tissue initially decline due to increased migration to MLNs (10, 13, 15, 16).

The growth factor GM-CSF is widely recognized as promoting differentiation and mobilization of myeloid cells in vivo and is frequently used to generate DCs from BM- or blood-derived precursors in vitro (17, 18). It is crucially involved in antimicrobial pulmonary host defense (19, 20) and ameliorates lung injury when applied systemically to IV-infected mice (21) by increasing size and activation of the alveolar macrophage pool (22, 23). Previously, 2 studies have demonstrated that GM-CSF drives the accumulation of CD11b+ DC populations in the gut lamina propria under homeostatic conditions (24, 25). More recently, GM-CSF was shown to expand radiosensitive langerin+CD103+ DCs in the skin and peripheral lymph nodes under steady-state and inflammatory conditions during autoimmune disease (26). With respect to the lung, however, the mechanisms mediating expansion and/or activation of parenchymal DC subsets during viral infection of the lower respiratory tract — and, in particular, the role of GM-CSF therein — remain to be defined.

Here, using a model of IV pneumonia, we elucidated a crucial role of IV-infected AECs in orchestrating pulmonary DC antiviral functions. Using BM chimeric and cell-specific depletion...
strategies, we showed that AEC GM-CSF released upon IV infection was required for expansion and activation of the CD103+ migratory DC pool and for an appropriate antiviral T cell–mediated immune response with recovery from IV-induced lung injury. Collectively, our data identified GM-CSF–dependent cross-talk between viral target cells and local DCs in the distal lung and highlighted the AEC GM-CSF/GM-CSFR axis as a potential therapeutic target to increase pulmonary DC antiviral functions in the context of IV-induced lung injury.

Results
AECs induce recovery from IV-induced lung injury by release of GM-CSF. AECs are primary targets for IVs and, at the same time, represent important effector cells in the host defense of the distal respiratory tract. Upon infection, they release cytokines that shape mononuclear phagocyte immune responses and initiate viral clearance. To address the role of GM-CSF in these processes, we tested whether AECs expressed GM-CSF in response to IV challenge. Indeed, both primary isolated and cultured murine and human AECs significantly upregulated Gm-csf mRNA upon in vitro PR8 infection, most prominent at 16 and 20 hours post infection, respectively (Figure 1A). Accordingly, AECs isolated from the lungs of PR8-infected mice showed increased Gm-csf expression compared with mock-infected controls at 3 days post infection (dpi; Figure 1B). To evaluate whether epithelial GM-CSF affected PR8-induced lung damage, we compared lung injury levels in WT mice, GM-CSF–deficient mice (referred to herein as Gm-csf−/−), and mice that express GM-CSF in AECs only (referred to herein as SPC-GM mice; see Methods). GM-CSF was released into the lungs of WT mice in response to PR8 infection and overexpressed constitutively and during IV infection in SPC-GM lungs compared with Gm-csf−/− mice (Figure 1C). Notably, GM-CSF protein was not detectable in the serum of WT or SPC-GM mice at baseline or after PR8 infection (data not shown). Strikingly, lung injury was highly increased in Gm-csf−/− compared with WT mice, and selective AEC GM-CSF expression in SPC-GM mice fully reverted increased alveolar injury, as demonstrated by analysis of Annexin V binding to CD45−CD31−EpCam+ LH cells. Alveolar albumin leakage analyzed after PR8 infection. The ratio of BALF and serum FITC fluorescence is expressed in AU. (F) Arterial oxygen saturation (SO₂).

Figure 1
AEC GM-CSF attenuates acute lung injury and increases survival in PR8 infection. (A) Gm-csf mRNA expression in primary murine (m-) or human (h-) AECs infected with PR8 in vitro. (B) Gm-csf mRNA induction in purified AECs from PR8-infected WT mice at 3 dpi. Expression of the type II AEC marker Stipc was additionally determined. (C) GM-CSF release in LHS of PR8-infected WT, Gm-csf−/−, SPC-GM, Gm-csf−/−→WT, and WT→Gm-csf−/− mice. (D) AEC apoptosis, determined by quantification of Annexin V binding to CD45−CD31−EpCam+ LH cells. (E) Alveolar albumin leakage analyzed after PR8 infection. The ratio of BALF and serum FITC fluorescence is expressed in AU. (F) Arterial oxygen saturation (SO₂). (G) Survival of WT and Gm-csf−/− mice infected with 500 PFU PR8 (n = 8 per group), WT and SPC-GM mice infected with 2,000 PFU PR8 (n = 8 per group), and Gm-csf−/−→WT and WT→Gm-csf−/− mice infected with 500 PFU PR8 (n = 9 per group). Data are mean ± SD. *P < 0.05, **P < 0.005 vs. mock-infected control (ctl) or as indicated by brackets.
In the lung, GM-CSF is expressed not only by AECs, but also by resident or recruited myeloid cells or further cell types (17), and various distal lung cell subsets were reported to be IV targets. We therefore analyzed in detail which alveolar cell populations were targets of PR8 during the course of infection. Significant numbers of type I and II AECs and CD11c+ leukocytes were PR8 infected by 3 dpi, whereas ECs were hardly and neutrophils (data not shown) were not infected (Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI62139DS1). We next analyzed which parenchymal cell types of the distal respiratory tract represented primary sources of GM-CSF after infection. Comparison of Gm-csf mRNA levels in flow-sorted type I and II AECs, bronchiolar epithelial cells (BECs; ref. 27), and endothelial cells revealed that type I AECs, BECs, and endothelial cells showed low baseline expression and no significant upregulation of GM-CSF at 3 dpi (Supplemental Figure 1C). Type II AECs showed the highest GM-CSF expression at baseline and, apart from bronchoalveolar lavage fluid (BALF) leukocytes (which were mainly composed of resident alveolar macrophages and neutrophils, Supplemental Figure 1B), were the only lung cell population that significantly upregulated Gm-csf mRNA upon PR8 challenge. Notably, separated and cultured AECs from lungs of untreated WT mice showed GM-CSF release into the supernatants compared with endothelial cells or alveolar macrophages (∼180 pg/ml; data not shown). Given that type II AECs represented the most frequent parenchymal cells in distal lungs (>90%; data not shown) and a substantial type II AEC proportion was PR8 infected, we concluded that AECs are the primary source of GM-CSF in the distal lung at baseline and in particular upon PR8 infection.

To further discriminate the role of AECs as opposed to myeloid GM-CSF in the observed effects, we infected WT or Gm-csf–/– mice that were reciprocally BM transplanted and, after reconstitution for 56 days, displayed resident alveolar macrophages (Supplemental Figure 2A) and circulating leukocytes of donor origin.

3655

WT→Gm-csf–/– mice (with WT myeloid GM-CSF expression) showed very low GM-CSF levels in their lungs and increased lung injury after PR8 infection compared with Gm-csf–/–→WT mice (with lung parenchymal cell GM-CSF expression), as demonstrated by analysis of AEC apoptosis (Figure 1, C and D). Moreover, PR8-induced mortality was highly increased in chimeric mice lacking epithelial GM-CSF expression compared with those lacking GM-CSF in myeloid cells (Figure 1G). Together, our data demonstrated that AECs are a primary source of GM-CSF in the PR8-infected lung and that lung parenchymal, but not myeloid cell–expressed, GM-CSF protects mice from IV-induced lung injury.

Lung-protective effects of AEC GM-CSF in IV pneumonia are mediated by pulmonary DCs. Recent reports demonstrated that AEC GM-CSF specifically enhanced host defense functions of resident alveolar macrophages during IV infection (22). To further dissect the contribution of lung mononuclear phagocyte subtypes to the beneficial effects of epithelial GM-CSF, we determined the numbers of macrophages and DCs in lung digest of WT, Gm-csf–/–, and SPC-GM mice. As shown in a representative FACS plot in Figure 2A, AEC GM-CSF was required for the presence of both CD11c–SiglecF–MHCIIint alveolar macrophages and lung CD11c–SiglecF–MHCIIhi DCs at baseline and during PR8 infection (7 dpi). We next addressed whether resident alveolar macrophages account for the observed beneficial effects of AEC GM-CSF. Depletion of alveolar macrophages prior to PR8 infection did not increase AEC apoptosis or albumin leakage in WT mice. Although macrophage depletion in SPC-GM mice resulted in increased IV-induced epithelial apoptosis, AEC apoptosis and alveolar albumin leakage were still significantly reduced in SPC-GM compared with WT mice (Figure 2B), suggestive of further macrophage-independent GM-CSF–mediated effects. Of note, PR8 titers in BALF at 7 dpi were not significantly increased in WT or SPC-GM mice after macrophage depletion (Supplemental Figure 2). To further dissect the role of alveolar macrophages versus DCs in our model, we generated BM chimeric WT and SPC-GM mice that were reconstituted with CD11c+/DTR BM after irradiation. In these chimeric mice, lung and MLN DCs were of CD11c+/DTR donor phenotype (Supplemental Figure 3, A and B), whereas the majority of alveolar macrophages was of CD11c+ recipient phenotype at 28 days post BM transplantation. This model allows selective depletion of lung and MLN CD11b+ and CD103+ DCs (CD11c+MHCIIhi) by systemic diphtheria toxin (DTX) application and of alveolar and lung parenchymal macrophages (CD11c+MHCIIhi) by intra-alveolar clodronate deposition (Figure 2, D and E). Whereas all control-treated CD11c–/DTR→SPC-GM mice survived PR8 infection, macrophage-depleted CD11c+→CD11b+CMC- GM mice showed a slightly decreased survival rate of 75%, indicative of a minor role for lung macrophages in the observed effects of AEC-derived GM-CSF on IV-induced mortality. In striking contrast, additional depletion of DCs resulted in a 100% mortality rate in CD11c+/DTR→SPC-GM mice at 8 dpi, with a comparable course of mortality in double-depleted CD11c+/DTR→WT mice (Figure 2E). These data indicate that AEC GM-CSF exerts its beneficial effects on IV-induced lung injury primarily by its effect on lung DCs.

AEC GM-CSF is required for both homeostasis at baseline and expansion of pulmonary DC subsets during IV infection. Given that steady-state homeostasis and IV-induced expansion of CD11c+MHCIIhi DCs in...
The lung parenchyma was dependent on AEC GM-CSF, we questioned whether expansion of different lung DC subsets shows an equivalent extent of GM-CSF dependency. Figure 3A shows a time course of total numbers of lung CD11c+MHCIIhi DCs in WT, Gm-csf−/−, and SPC-GM mice, demonstrating their GM-CSF–dependent expansion throughout the course of PR8 infection. DC subset differentiation (see Supplemental Figure 4 for gating strategy) revealed that the amount of CD11b+ DCs and mo-DCs at baseline conditions was independent of AEC GM-CSF, but both DC subsets accumulated to high numbers in the lung parenchyma after PR8 infection until 7 dpi only in the presence of AEC GM-CSF (Figure 3, B and C). In contrast, CD103+ DC numbers generally declined until 5–7 dpi in WT and SPC-GM mice, and their presence at baseline and throughout the course of infection was widely reduced in Gm-csf−/− mice (Figure 3D), which indicates that steady-state homeostasis of CD103+ DCs was GM-CSF dependent and that selective AEC overexpression of GM-CSF was sufficient to restore lung CD103+ DC composition. Figure 3E shows a representative FACS plot of DC subsets in the 3 treatment groups at baseline (CD103+ and CD11b+ DCs) and 7 dpi (mo-DCs and CD11b+ DCs). Of note, accumulation of CD11c+MHCIIloB220+ plasmacytoid DCs in infected lungs was not dependent on GM-CSF (data not shown).

AEC GM-CSF mediates activation of CD103+ DCs and migration to the draining MLNs under steady-state conditions and upon PR8 infection. (A and B) WT, Gm-csf−/−, SPC-GM, WT→Gm-csf−/−, and Gm-csf−/−→WT mice were PR8 infected, and the fractions of CD11b+ DCs (A) and CD103+ DCs (B) in MLNs were quantified by flow cytometry using the gating strategy in C (red gates, CD103+ DCs; blue gates, CD11b+ DCs). (D) Migratory CD103+ DCs from LH of WT mice were additionally stained for IV NP or control IgG at 5 dpi. Representative FACS plot depicts the NP+ fraction of CD45+CD11c+MHCII+CD103+ DCs. (E) Comparative flow cytometric quantification of CD80 and CD86 expression on lung and MLN CD103+ DCs after PR8 infection. Values are given as mean intensities ×1,000 of PE (CD80) and PE-Cy7 (CD86) fluorescence. Data are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.005.
infected WT, Gm-csf–/– and SPC-GM mice. mo-DCs were virtually undetectable in MLNs (data not shown). Unlike CD11b+ and CD8+ DCs, which were found in low amounts in MLNs of uninfected and infected mice of all treatment groups (Figure 4, A and C, and data not shown), CD103+ DCs accumulated in the draining MLNs in a GM-CSF–dependent manner during PR8 infection (Figure 4, B and C). Of note, lack of epithelial as opposed to myeloid cell GM-CSF caused reduced numbers of CD103+ DCs in MLNs of WT→Gm-csf–/– versus Gm-csf–/–→WT chimeric mice, and AEC overexpression of GM-CSF in SPC-GM mice even resulted in significantly increased CD103+ DC numbers at baseline and at 7 dpi compared with WT mice (Figure 4B), which suggests that AEC GM-CSF increases migration of lung CD103+ DCs to draining MLNs. Migration and activation of DCs is, at least in part, induced by sampling and processing of foreign antigen at the site of infection. In fact, approximately 4% of pulmonary CD103+ DCs stained positive for IV nucleoprotein (NP; Figure 4D), indicative of antigen uptake by this DC subset in the lung parenchyma, a characteristic feature of migratory DCs. To address whether epithelial GM-CSF is specifically required for CD103+ DC activation, surface expression of DC activation markers CD80 and CD86 were quantified in all treatment groups. Indeed, expression of activation markers on lung homogenate (LH) CD103+ DCs was, at least in part, depen

---

**Figure 5**

AEC GM-CSF is required for alveolar antiviral CD8+ T cell responses and PR8 clearance from mouse lungs. (A) Absolute numbers of CD4+ and CD8+ T lymphocytes in BALF were determined by counting BALF cells and by flow cytometric quantification of the CD45+SSC–/CD3+CD4+ and CD45+SSC–/CD3+CD8+ fractions, respectively, after PR8 infection in WT, Gm-csf–/–, and SPC-GM mice. (B) Antigen-specific CD4+ and CD8+ T cell numbers in BALF or spleen, determined by analysis of the NPpeptide/H2-Db dextramer+ or the IFN-γ+ fraction of CD45+SSC–/CD3+CD4+ and CD45+SSC–/CD3+CD8+ cells, respectively, after PR8 infection (7 dpi). (C) Representative FACS plots of the IFN-γ analysis; percent values of the respective IFN-γ+ proportions are shown in each plot. (D) PR8 titers in WT, Gm-csf–/–, SPC-GM, WT→Gm-csf–/–, and Gm-csf–/–→WT mice, quantified from BALF at the indicated dpi by standard plaque assay and given as PFU/ml × log10 (detection limit, 101 PFU/ml × log10). Data are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.005. SSC, side scatter.
dent on AEC GM-CSF in uninfected and PR8-infected mice. After migration to MLNs, CD80 and CD86 expression was still reduced in CD103+ DCs in Gm-csf–/– mice at 7 dpi (Figure 4E). Together, our data demonstrated that AEC GM-CSF mediates maturation and MLN migration of pulmonary CD103+ DCs.

AEC GM-CSF mediates recruitment of activated CD8+ T cells, associated with IV clearance from the lungs. Migratory CD103+ DCs were shown to preferentially drive antigen presentation to naive CD8+ T cells in the MLNs following IV infection (12), which are then recruited to the lung to clear infection. To test the role of epithelial GM-CSF herein, we quantified numbers of T cell subsets in the alveolar space during the course of PR8 infection. CD4+ and CD8+ T cells accumulated in BALF until 11 dpi in WT mice, whereas GM-CSF deficiency abrogated this T cell response. Epithelial GM-CSF expression, however, largely restored alveolar T cell accumulation in SPC-GM mice (Figure 5A). Of note, AEC GM-CSF was required for the accumulation of antigen-specific NPpeptid-dextramer+ or IFN-γ+CD4+ and IFN-γ+CD8+ T cells in the airspaces or in spleen (Figure 5B). Figure 5C depicts representative FACS plots showing the proportion of IFN-γ+CD4+ and IFN-γ+CD8+ T cells in BALF in the 3 treatment groups at 7 dpi. Accordingly, lung viral loads were significantly increased in Gm-csf–/– mice.

Figure 6
Lung-protective effects of AEC GM-CSF are mediated by CD103+ lung DCs. (A) Treatment protocol. WT or SPC-GM mice were transplanted 1 × 10^6 Langerin–/–DTR BM cells to generate Langerin–/–DTR→WT or Langerin–/–DTR→SPC-GM chimeric mice. 26 days later, when >90% of lung DCs were of Langerin–/–DTR donor phenotype, mice were treated with either DTX or PBS to deplete CD103+ DCs, then infected with PR8 48 hours later for further analyses at 35 dpi. (B) At 28 dpi, efficacy of CD103+ DC depletion after PBS or DTX treatment was analyzed by FACS. The CD103+ fraction of CD45+CD11c+MHCIIhi LH cells was determined after gating on the CD45+CD11c+MHCIIhi population; percentage values are given. At 7 dpi, the fractions of CD103+ and CD11b+ DCs in MLNs were quantified (C), using the gating strategy in Figure 3C; the proportions of IFN-γ+ of CD4+ and CD8+ T cells in BALF were quantified (D), as outlined in Figure 5C; and the fractions of NP+ EpCam–CD45– epithelial cells in LHs were determined by FACS (E), depicted as absolute numbers in Langerin–/–DTR→WT and Langerin–/–DTR→SPC-GM chimeric mice after PBS or DTX application. (F) AEC apoptosis in chimeric mice after PBS or DTX application was analyzed by FACS quantification of annexin V binding to CD45–CD31–EpCam– LH cells at 7 dpi, and (G) total protein was determined in BALF. (H) Survival of PR8-infected chimeric mice after PBS or DTX treatment (n = 8–13). Data are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.005.
compared with WT and SPC-GM mice (Figure 5D). Of note, AEC GM-CSF, but not leukocyte-expressed GM-CSF, was required for efficient PR8 clearance at 7 dpi, as shown in WT → Gm-csf−/− and Gm-csf−/−→WT chimeric mice, and AEC GM-CSF overexpression in SPC-GM mice even resulted in accelerated clearance compared with WT mice (Figure 5D). We concluded that AEC GM-CSF mediates recruitment of IFN-γ+ T cells to the lung, which is associated with enhanced clearance of infection.

AEC GM-CSF is required for effective host defense functions of CD103+ DCs and for recovery from IV-induced lung injury. To definitely demonstrate the role of CD103+ DC activation in response to AEC GM-CSF for effective antiviral host defense and recovery from lung damage, we generated BM chimeras using WT or SPC-GM mice that were irradiated and reconstituted with Langerin+/DTR BM for 28 days. In this model, all pulmonary CD103+ DCs were of Langerin+/DTR (donor) phenotype (data not shown) and selectively depleted by DTX application 48 hours prior to PR8 infection (Figure 6A). The representative FACS plots in Figure 6B demonstrate high depletion efficiency in lungs of Langerin+/DTR chimeric mice treated with DTX compared with PBS-treated controls. Flow cytometric quantification of DCs in draining MLNs at 7 dpi with PR8 revealed that the CD103+, but not the CD11b+, DC subset was significantly reduced in DTX- versus PBS-treated chimeras of both WT and SPC-GM recipient phenotypes (Figure 6C). CD103+ DC depletion resulted in reduced numbers of IFN-γ+CD4+ and IFN-γ+CD8+ T cells in BALF at 7 dpi. Of note, CD8+ cytotoxic T cells in particular were reduced to equal low numbers in BALF of both WT and SPC-GM chimeric mice (Figure 6D). Accordingly, IV clearance decreased in WT and SPC-GM chimeric mice after DTX treatment to comparable levels at 7 dpi (Figure 6E), which indicates that the beneficial effect of AEC SPC-GM overexpression on antiviral host defense was completely abrogated upon CD103+ DC depletion. Analyses of lung injury parameters revealed similarly increased AEC apoptosis and alveolar protein leakage in DTX-treated WT and SPC-GM chimeric mice compared with PBS-treated controls at 7 dpi (Figure 6, F and G). Finally, whereas all PBS-treated SPC-GM chimeras survived infection until 21 dpi, survival of DTX-treated SPC-GM and WT chimeric mice was substantially decreased (Figure 6H). Together, these data demonstrated that pulmonary CD103+ DCs are essential for AEC GM-CSF-mediated host defense functions, which lead to recovery from lung injury in PR8 pneumonia.

**Intrathelial application of recombinant GM-CSF increases CD103+ DC migration and host defense and attenuates IV-induced lung injury.** The beneficial effects of high AEC GM-CSF levels in IV pneumonia in SPC-GM mice prompted us to evaluate whether exogenously applied GM-CSF would be similarly protective in our model. We therefore infected WT mice with PR8 and on the same day applied a single dose of recombinant GM-CSF intratracheally (i.t.). CD103+ DC numbers were significantly increased at 7 dpi in MLNs of GM-CSF– versus control-treated mice (Figure 7A). Concomitantly, we found significantly increased numbers of CD4+ and CD8+ T cells in BALF (Figure 7B) and reduced viral titers at 7 dpi (P = 0.05; Figure 7C) after GM-CSF treatment. In addition, PR8-induced lung injury at 7 dpi was strikingly attenuated in GM-CSF–treated mice, as demonstrated by analyses of AEC apoptosis, alveolar albumin leakage, and arterial oxygen saturation and partial CO2 pressure (pCO2; F) were determined. Data are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.005.

**Figure 7** GM-CSF application i.t. increases CD103+ DC migration, alveolar T lymphocyte recruitment, and viral clearance, which is associated with attenuated lung injury after PR8 infection. WT mice were PR8 infected (or mock infected in selected experiments), followed by i.t. application of 5 μg GM-CSF or PBS plus 0.1% BSA. (A) At 7 dpi, the fraction of CD103+ DCs in MLNs was quantified by flow cytometry. (B) Absolute numbers of CD4+ and CD8+ T lymphocytes in BALF were determined by counting BALF cells and flow cytometric quantification of the CD45–SSC–CD3+CD4+ and CD45–SSC–CD3+CD8+ fractions, respectively, and (C) PR8 titers were determined from BALF by standard plaque assay. (D–F) At 7 dpi, AEC apoptosis (D), alveolar albumin leakage (given as ratio of BALF and serum FITC fluorescence in arbitrary units; E), and arterial oxygen saturation and partial CO2 pressure (pCO2; F) were determined. Data are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.005.
IV pneumonia is characterized by infection of distal bronchiolar and, importantly, AECs and frequently progresses to acute lung injury/ARDS with poor outcome. Rapid onset of effective host defense strategies is therefore crucial for attenuation of or recovery from IV-induced lung injury. Pulmonary DC subsets are key regulators of antiviral innate and adaptive immune responses (13, 28–30). It is widely recognized that conventional DCs or their precursors are expanded at sites of inflammation or infection by defined chemokine-receptor interactions (16, 31, 32), and that they are armed with a variety of pattern recognition receptors enabling them to sense foreign antigen, including viruses, and inducing their further activation (33). Yet, the mechanisms of communication between primary viral target cells in the distal lung and juxtaposed parenchymal DCs, which might be a critical link for infection-driven DC expansion or full activation, are poorly defined. We therefore tested the hypothesis that AEC-derived signals mediate expansion and host defense functions of pulmonary DC subsets in a mouse model of severe IV pneumonia. In fact, our data demonstrated that IVs induce the growth factor GM-CSF in AECs in vitro and in vivo, which was required not only for expansion of mo-DCs and CD11b+ DCs in the lung, but particularly for activation and migration of CD103+ DCs to the draining MLNs. By its effects on CD103+ DCs, epithelial GM-CSF increases recruitment of IFN-γ+CD4+ and IFN-γ+CD8+ T cells to the air spaces, accelerates IV clearance, and mediates recovery from epithelial injury.

**Discussion**

IV pneumonia is characterized by infection of distal bronchiolar and, importantly, AECs and frequently progresses to acute lung injury/ARDS with poor outcome. Rapid onset of effective host defense strategies is therefore crucial for attenuation of or recovery from IV-induced lung injury. Pulmonary DC subsets are key regulators of antiviral innate and adaptive immune responses (13, 28–30). It is widely recognized that conventional DCs or their precursors are expanded at sites of inflammation or infection by defined chemokine-receptor interactions (16, 31, 32), and that they are armed with a variety of pattern recognition receptors enabling them to sense foreign antigen, including viruses, and inducing their further activation (33). Yet, the mechanisms of communication between primary viral target cells in the distal lung and juxtaposed parenchymal DCs, which might be a critical link for infection-driven DC expansion or full activation, are poorly defined. We therefore tested the hypothesis that AEC-derived signals mediate expansion and host defense functions of pulmonary DC subsets in a mouse model of severe IV pneumonia. In fact, our data demonstrated that IVs induce the growth factor GM-CSF in AECs in vitro and in vivo, which was required not only for expansion of mo-DCs and CD11b+ DCs in the lung, but particularly for activation and migration of CD103+ DCs to the draining MLNs. By its effects on CD103+ DCs, epithelial GM-CSF increases recruitment of IFN-γ+CD4+ and IFN-γ+CD8+ T cells to the air spaces, accelerates IV clearance, and mediates recovery from epithelial injury in terms of improved barrier function and gas exchange (Figure 8).

Initially considered to function solely as a physical barrier providing gas exchange, the alveolar epithelium is now increasingly recognized as an important effector in fine-tuning antiviral immune responses at both onset and resolution of inflammation (4, 5, 34). Mononuclear phagocyte homeostasis, in particular, is controlled primarily from increased recruitment of inflammatory precursors, rather than from local expansion of the tissue-resident subepithelial CD11b+ DC pool. It is likely that pulmonary GM-CSF directly or indirectly mediates extravasation of mo-DC precursors that further differentiate toward a CD11b+ DC phenotype within the inflammatory alveolar microenvironment.

In contrast to our findings on CD11b+ DCs, CD103+ DC development in the lung parenchyma was strongly dependent on GM-CSF in noninflamatory conditions. Expression of AEC GM-CSF in SPC-GM mice was sufficient to revert the reduced CD103+ DC numbers observed in Gm-csf−/− animals (Figure 3D). Given that CD103+ DCs are replenished from circulating precursors (15), we speculate that lung-expressed GM-CSF might provide either a direct or an indirect recruitment signal for blood-borne prec-DCs or induce local proliferation of differentiated CD103+ parenchymal DCs. Of note, we did not detect any leakage of epithelial GM-CSF into the circulation in WT or SPC-GM mice (data not shown). Interestingly, constitutive alveolar overexpression of GM-CSF...
did not further increase the numbers of steady-state lung CD103+ DCs in SPC-GM versus WT mice, with BALF GM-CSF levels of 595 ± 75 pg/ml compared with 47 ± 14 pg/ml in untreated mice (data not shown). This might be due to the requirement of a second signal, such as Flt3L, that additionally determines the numbers of tissue CD103+ DCs in steady state. Remarkably, baseline CD103+ DC numbers in draining MLNs were significantly increased upon conditional and exclusive GM-CSF overexpression in the lung. Although we lack direct evidence that CD103+ DCs accumulating in MLNs are lung derived, these data suggest an enhanced migratory capacity of AEC GM-CSF–stimulated pulmonary CD103+ DCs, which is likely due to increased baseline activation of CD103+ DCs in terms of CD80 expression, as observed in SPC-GM mice (Figure 4, B and E).

GM-CSF was widely used in clinical studies to attract or generate DCs at sites of disease (46, 47). The question of whether and to what extent GM-CSF controls the homeostasis of resident organ DCs and their functional properties during inflammatory diseases, however, is still controversial. Whereas systemic GM-CSF is not involved in lymphoid organ DC development in the steady state (48), it was previously shown to play a role during inflammation involved in lymphoid organ DC development in the steady state (49), which suggests that GM-CSF might preferentially regulate the development of inflammatory DCs. Recently, however, several studies using GM-CSFR–deficient mice elucidated a role of the GM-CSF/GM-CSFR axis in the development of steady-state DCs in nonlymphoid tissues. Whereas Bogunovic et al. showed that GM-CSF controls the development of CD103+CD11b+ DCs, but not CD103+CD11b+ DCs, in the gut lamina propria (24), another study revealed that lack of GM-CSFR compromises the development of lamina propria CD11b+ DCs, but not CD11b+ DCs (25).

In the skin, GM-CSF was directly required for the accumulation of langerin+CD103+ DCs in peripheral lymph nodes under both steady-state and inflammatory conditions (26). With respect to the lung, Ginhoux et al. showed that GM-CSF overexpression accelerates viral clearance by 3 dpi, which is likely to occur to an undefined extent in our model. In addition, we previously demonstrated that lung-recruited inflammatory CD11b+ DCs are a primary source of innate immune mediators like TNF-α or IL-12p40 (45).

It is well established that AEC GM-CSF improves innate immune responses of myeloid cells, in particular alveolar macrophages, and increases their survival, which was recently shown to be protective during IV infection in vivo (22, 23, 52). Our present data suggest that GM-CSF overexpression accelerates viral clearance by 3 dpi, when innate immunity responses are prominent. Using WT and SPC-GM chimeric mice transplanted with CD11c+ CD11b+ BM to deplete DCs, combined with clodronate-induced depletion of alveolar macrophages, we differentially addressed their respective contributions in the context of high-level AEC GM-CSF. Indeed, depletion of macrophages alone reduced survival by 25% compared with nondepleted mice after IV challenge. However, additional depletion of lung DCs before infection was 100% lethal, regardless of whether these mice displayed normal or increased GM-CSF levels in their lungs (Figure 2). We therefore conclude that the lung-protective effects of GM-CSF in our model are largely mediated through its actions on DCs, although improved macrophage (or neutrophil) activity in SPC-GM mice likely contributes to early antiviral host defense and prevention of lung injury. In this respect, we and others have shown that AEC GM-CSF critically mediates epithelial proliferation in inflammatory or hyperoxic lung injury, thereby actively supporting repair and restoration of barrier function and return to tissue homeostasis (39, 53). Therefore, based on the beneficial effects observed for i.t. GM-CSF treatment regarding CD103+ DC antiviral functions in our model (Figure 7) and its beneficial effects described in others (21),
local therapeutic application of GM-CSF might be considered to increase mononuclear phagocyte-mediated innate and adaptive host defense and to accelerate epithelial repair processes during severe IV pneumonia.

**Methods**

**Reagents.** The following anti-mouse mAbs/secondary reagents were used for flow cytometry: CD45.1-PE and -FITC (clone A20), CD45-FITC, -PE, and -APC (clone 30F-11), CD45.2-PerCp-Cy5.5 (clone 104), 1-A-I-E-FTTC (clone 2G9), Siglec-F-PE (clone E502440), CD31-PE, (clone MEK13.3), CD4-FITC (clone RM4-4), CD8-FITC (clone 30-5A11), CD11c-APC (clone HL3), CD11b-PE (clone M1/70), B220-PE-Cy7 (clone RA3-6B2), CD80-PE (clone 16-10A1), CD86-PE-Cy7 (clone GL1), and isotype-matched control IgG Abs (all BD Biosciences — PharMingen); CD45.2-APC-Cy7 (clone 104), CD3-PerCP (clone 145-2C11), CD103-PerCP (clone 2E7), EpCam-APC-Cy7 and -eFluor505 (clone g8.8), CD31-Alexa Fluor 488 (clone MEK13.3), T11/ podoplanin-PE-Cy7 (clone 8.1.1), CD49-FPE (clone GoH3), IFN-γ-APC (clone XM1.2), and -APC (all Biolegend); F4/80-Alexa Fluor 647 (clone CLA1-1; Caltag); anti-influenza NP (Biosciences); NP-FITC (clone 431; Abcam), pro–surfactant protein C (pro-SPC; Millipore), annexin V-Alexa Fluor 647 (Molecular Probes); anti-mouse Ig-Alexa Fluor 488 (Molecular Probes). Propidium iodide for dead cell exclusion was purchased from Sigma-Aldrich. Influenza antigen-specific T cells were detected by FACS using PE-labeled H-2Db dextramer with respective mAbs. B6.SJL-lpr/lpr mice were purchased from The Jackson Laboratory. CD41c+/DTR mice were generated with DIVA software (BD Biosciences). 1–5 × 105 cells per sample of BALF, LH, or MLNs were fixed for 15 minutes in cold 1% paraformaldehyde and incubated with fluorochrome-labeled antibodies for 20 minutes at 4°C. For intracellular stainings (NP, IFN-γ, pro-SPC), cells were subsequently incubated for 15 minutes in 0.2% saponin in PBS and incubated with anti-NP mAb, IFN-γ-APC, or anti–pro-SPC or respective isotype control mAbs for 30 minutes at 4°C, followed by 10 minutes incubation with TrueBlue peroxidase substrate (KPL) before quantification of stained plaques (detection limit, 10 PFU/ml BALF).

Flow cytometry and cell sorting. Multiparameter flow cytometry was performed using FACSCanto and LSR Fortessa flow cytometers equipped with DIVA software (BD Biosciences). 1–5 × 105 cells per sample of BALF, LH, or MLNs were fixed for 15 minutes in cold 1% paraformaldehyde and incubated with fluorochrome-labeled antibodies for 20 minutes at 4°C. For intracellular stainings (NP, IFN-γ, pro-SPC), cells were subsequently incubated for 15 minutes in 0.2% saponin in PBS and incubated with anti-NP mAb, IFN-γ-APC, or anti–pro-SPC or respective isotype control mAbs for 30 minutes at 4°C, followed by 10 minutes incubation with secondary antimouse/Alexa Fluor 488 Ab in case of NP staining. Apoptosis analysis was performed on freshly prepared, nonfixed, nonpermeabilized LNs. Prior to antibody incubation, the samples were washed and resuspended in annexin V buffer for 20 minutes at 4°C. Cell sorting was performed using a FACSAriaII equipped with 4 lasers and DIVA Software (BD Biosciences). The purities of sorted lung cell populations were always >93%.

ELISA. GM-CSF levels in LHs and serum were analyzed using a commercially available ELISA kit (R&D Systems) according to the manufacturer’s instructions (detection limit, 1.8 pg/ml).

**Isolation, culture, and infection of murine and human AECs.** Murine AECs were isolated as described previously (39, 59). LHs were prepared as described above; the single-cell suspension was centrifuged, resuspended, and incubated with biotinylated rat anti-mouse CD45, CD16/32, and CD31 mAbs (all BD Biosciences — PharMingen) to deplete leukocytes and endothelial cells for 30 minutes. The contaminating cell types were removed by incuba-
tion with streptavidin-link magnetic particles and subsequent magnetic separation. The supernatant was recovered, and cells were kept in DMEM supplemented with FCS, HEPES, t-glutamine, and penicillin-streptomycin. AECs from human lung tissue were isolated as described previously (58). The lung tissue was minced and washed extensively in HAM F12 medium containing 10% FCS and antibiotics, filtered through 100-μm pore size filters (BD Biosciences), and subsequently digested with Dispaase II (2.5 mg/ml; Boehringer) in the presence of 2 mM calcium and 1.3 mM magnesium for 180 minutes at 37°C under continuous rotation. A cell-rich suspension was obtained by sequential filtration through sterile 100- and 40-μm filters (BD Biosciences) and 20-μm pore size meshes (Milipore). AECs were separated by ficoll (Ficoll Paque; Amersham Pharmacia Biotech) density centrifugation (1,300 g, 15 minutes at 21°C), followed by depleting the interfacial cells of contaminating leukocytes by anti-CD45 magnetic beads (Milteny Biotech). Final cell suspensions consisted of >95% AECs, as assessed by FACS. Viability was always >95%, as analyzed by trypan blue dye exclusion. AECs were cultured for 5 (murine) or 7 (human) days in FCS- and antibiotics-supplemented DMEM and HAM F12 medium, respectively. Confluent AECs were infected or mock-infected with PR8 diluted in PBS at the indicated MOI as previously reported (59).

Creation of BM chimeric mice. BM cells were isolated under sterile conditions from the tibias and femurs of WT, Gm-csf–/–, or Langerin–/– donor mice as described previously (4). 1 × 10⁸ BM cells were i.v. injected into lethally irradiated WT, Gm-csf–/–, or SPC-GM recipient mice after total body irradiation (6 Gy). As engraftment controls, WT BM cells (expressing the CD45.2 allelogrunt) were transplanted into CD45.1 allelogrunt-expressing C57BL/6 mice (n = 4 per transplantation experiment), and the proportion of CD45.2 myeloid blood leukocytes was analyzed by flow cytometry. BM engraftment was 94.4±1% at 4 or 8 weeks post transplantation. Chimeric mice were housed under SPF conditions prior to PR8 infection.

RNA isolation and real-time RT-PCR. RNA from cultured AECs for from murine lungs was isolated by PeqGold Total RNA kit (Peqlab) and RNaseasy Kit (Qiagen), respectively, following the manufacturer’s protocol. cDNA synthesis, reagents, and incubation steps were as previously described (39). Relative mRNA quantification was done by real-time RT-PCR, using actin as a reference gene. Reactions were performed in an ABI 7900 Sequence Detection System (Applied Biosystems) using SYBR-Green I as fluorescent probe in 25-μl reactions containing 12.5 ng converted cDNA sample, 1× qPCR Mastermix for SYBR Green I (Invitrogen), and 45 pmol forward and reverse primers. The following intron-spanning primers were used: murine actin forward, 5′-GGAACAGTGATAGGCCCCCATCA-3′; murine GM-CSF reverse, 5′-GAATATCTTACGGGGTCTTC-3′; murine SP-C forward, 5′-CTCCT- GATGGAGTGTCACC-3′; murine SP-C reverse, 5′-CAGAGCCTCCA TACATCACC-3′; human actin forward, 5′-CTGGAGATGGTG GGAGGC-3′; human actin reverse, 5′-TCAACTCTGCTCAGAAGTG-3′; human GM-CSF forward, 5′-GGTCTACCTGAGGCTGCTC-3′; human GM-CSF reverse, 5′-ACTAACAGGAGCTGCCC-3′. Relative gene abundance to housekeeping gene was calculated as a ΔCt value (namely, ΔCtreference – ΔCtsubject), and data are presented as ACT or fold expression (2^ΔCt) values between treatment groups.

Statistics. All data are given as mean ± SD. Statistical significance between 2 groups was estimated using the unpaired Student’s t test or ANOVA and post-hoc Tukey HSD for comparison of 3 groups and calculated with SPSS for Windows. A P value less than 0.05 was considered significant.

Study approval. All animal experiments were approved by the regional authorities of the State of Hesse (Regierungspräsidium Giessen). Human lung tissue was obtained from patients who underwent lobectomy after informed written consent (Departments of Pathology and Surgery, Justus-Liebig-University, Giessen). Use of human lung tissue samples was approved by the University of Giessen Ethics Committee.

Acknowledgments

This work was supported by the German Research Foundation (SFB/TR84 “Innate Immunity of the lung” grants B2/3, grant LO271/4-1, and Excellence Cluster Cardio-Pulmonary System [ECCPS]), by the German Federal Ministry of Research and Education (“FluResearchNet” grant 01KI1006M and Clinical Research Group “Infectious Diseases” grant 01KI0770), and by the von Behring-Röntgen Foundation of the Universities of Giessen and Marburg. B.E. Clausen is a VIDI-fellow of the Netherlands Organization for Scientific Research (NWO). The authors thank R. Winkler, J. Bespalowa, and D. Hensel for excellent technical assistance and J. Whitsett for providing Gm-csf–/– and SPC-GM mice.

Received for publication November 25, 2011, and accepted in revised form July 19, 2012.

Address correspondence to: Susanne Herold, University of Giessen Lung Center, Department of Internal Medicine II, Klinikstr. 36, D-35392 Giessen, Germany. Phone: 49.641.985.42552; Fax: 49.641.985.42568; E-mail: Susanne.Herold@innere.med.uni- giessen.de.


26. King IL, Kroenke MA, Segal BM. GM-CSF.


